Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to ...
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results